Astellas Pharma took a big step into gene therapies when it announced an agreement at the end of 2019 to acquire Audentes Therapeutics for $3 billion. The company continues to build on that acquisition and has just completed construction on a 154,000 square foot, state-of the art cell and gene therapy facility to bring together teams dispersed across 20 locations. We spoke Ha Tran, medical head of cell and gene therapy for Astellas Pharma, about the company’s vision for cell and gene therapies, its efforts to restart trials for its X-linked myotubular myopathy gene therapy, and how it is looking to other programs beyond that.
How to Advocate for Yourself as You Battle Cancer
Targeting Neuroinflammation to Treat ALS
Leveraging Community Partnerships to Address a Rare Disease Behind a Medical Mystery in New Mexico
Accelerating Gene Editing Therapies for Rare, Neurological Conditions
Inhibiting Electrical Activity in Rare, Seizure Disorders
Improving the Function and Usability of Clothing for People with Disabilities
Treating Cardiopulmonary Disease with Inhaled Targeted Therapies
A Patient-Driven Registry Focused on Health-Related Quality of Life Data
An Ally for the Undiagnosed Emerges
Help for Rare Disease Patients That’s Just a Click Away
Diagnosing Autism with a Single Strand of Hair
Bringing Regenerative Medicine to a Rare Bone Condition in Children
Bringing Precision to CRISPR-Based Genome Editing
Capturing Patients’ Experience in Their Daily Lives
From One to Many
A Nasal Spray to Curb Excessive Eating in Prader-Willi
How One Foundation Is Laying the Groundwork to Advance Treatments for an Ultra-Rare Disease
Forging a New Path for Medicine
Restoring Hearing through Gene Therapies
Creating a Sustainable Reimbursement Model for Ultra-Rare Therapies
Create your
podcast in
minutes
It is Free
The Commercial Edge: Unleash the Power of People
The emPOWERed Half Hour
NABOR® TALKS
U.S Property Podcast
Aligned Money Show
The Ramsey Show
Planet Money